Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
MHLW to Introduce Guidelines for Sales Reps’ Activities, Calling for the Creation of Supervising Offices
To read the full story
Related Article
- Over 30% of Drug Makers Spot Inappropriate Promotions after Guidelines Enforcement
June 16, 2021
- MHLW to Run Fresh Survey on Drug Makers’ Responses to Promotion Guidelines
January 13, 2021
- Promotion Guidelines Now in Full Effect, MHLW Starts Survey to Capture Leading Examples of Company Set-Ups
December 17, 2019
- Wholesalers Working Out Systems to Comply with Promotion Guidelines, Show Mixed Approaches to External Oversight
October 8, 2019
- Drug Makers, Wholesalers Establishing Supervisory Divisions as Detailing Guidelines Rollout Nears
March 15, 2019
- MHLW to Follow Up on Drug Makers’ Efforts to Observe New Detailing Guidelines
January 7, 2019
- MHLW Issues Guidelines on Detailing Activities by Sales Reps; to Take Effect Next April
September 27, 2018
- Regulatory Science Society Says “No” to Off-Label Info Supply by Drug Reps Conditionally OK’ed in Draft MHLW GLs
August 24, 2018
- MHLW to Draft GL on Detailing Activities by Drug Reps as Early as Summer
April 13, 2018
- MHLW Still Pondering Steps to Ensure Proper Sales Activities by Drug Reps
February 28, 2018
REGULATORY
- MHLW Project Team Compiles Interim Proposal for Supporting Healthcare Startups
April 30, 2024
- Govt’s Healthcare Advisors Call for Bolstering AMED Staff: 2025-2029 Strategy
April 30, 2024
- Japan’s 1st Eylea Biosimilar Now in Line for Approval, AMD Dropped for Patent Reasons
April 30, 2024
- MHLW’s Generic Industry Panel to Call for 5-Year Intensive Reform Period
April 26, 2024
- Jaypirca, Prevymis, Relvar and More on MHLW Panel Agenda for May 9
April 26, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…